Challenges assessing clinical endpoints in early Huntington disease
- 10 November 2010
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 25 (15), 2595-2603
- https://doi.org/10.1002/mds.23337
Abstract
The basic aim of this study was to evaluate the current accepted standard clinical endpoint for the earliest‐studied HD participants likely to be recruited into clinical trials. As the advent of genetic testing for HD, it is possible to identify gene carriers before the diagnosis of disease, which opens up the possibility of clinical trials of disease‐modifying treatments in clinically asymptomatic persons. Current accepted standard clinical endpoints were examined as part of a multinational, 32‐site, longitudinal, observational study of 786 research participants currently in the HD prodrome (gene‐positive but not clinically diagnosed). Clinical signs and symptoms were used to prospectively predict functional loss as assessed by current accepted standard endpoints over 8 years of follow‐up. Functional capacity measures were not sensitive for HD in the prodrome; over 88% scored at ceiling. Prospective evaluation revealed that the first functional loss was in their accustomed work. In a survival analysis, motor, cognitive, and psychiatric measures were all predictors of job change. To our knowledge, this is the first prospective study ever conducted on the emergence of functional loss secondary to brain disease. We conclude that future clinical trials designed for very early disease will require the development of new and more sensitive measures of real‐life function. © 2010 Movement Disorder SocietyFunding Information
- National Institutes for Health
- National Institute of Neurological Disorders and Stroke (NS40068)
- CHDI Foundation, Inc
- PREDICT-HD
- National Research Roster for Huntington Disease Patients and Families
This publication has 28 references indexed in Scilit:
- Earliest functional declines in Huntington diseasePsychiatry Research, 2010
- CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approachesNeuropsychiatric Genetics, Part B of the American Journal of Medical Genetics (AJMG), 2010
- Detection of Huntington's disease decades before diagnosis: the Predict-HD studyJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Can clinical outcomes be used to detect neuroprotection in multiple sclerosis?Neurology, 2007
- Critical Periods of Suicide Risk in Huntington’s DiseaseAmerican Journal of Psychiatry, 2005
- Dementia diagnostics made evidence-based: a critical evaluation of cognitive assessment tools in clinical dementia diagnosticsCurrent Opinion in Psychiatry, 2004
- A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG lengthClinical Genetics, 2004
- Neuroprotection for Parkinson's disease: Prospects and promisesAnnals of Neurology, 2003
- Behavioural abnormalities contribute to functional decline in Huntington's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Neuropsychiatric aspects of Huntington's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2001